.png)
Severe asthma is a chronic condition that presents significant challenges for both patients and healthcare systems worldwide. Characterized by persistent, debilitating symptoms, frequent exacerbations, and limited response to standard treatments, it represents a more complex and demanding aspect of asthma care. As the global asthma prevalence continues to rise, so too does the need for specialized treatments and solutions. In this blog, we explore the key factors driving the growth of the severe asthma market and how advancements in diagnostics, treatment options, and research are transforming the landscape of care.
The prevalence of severe asthma is on the rise, particularly in key regions such as the United States, Japan, and Europe. As of 2023, severe asthma accounted for approximately 5.1 million diagnosed cases in the seven major markets (7MM)—which include the U.S., EU4 (Germany, France, Italy, and Spain), the UK, and Japan. Among these, the U.S. reported the highest number of cases, with around 2 million severe asthma patients. This number is expected to increase significantly by 2034, spurring demand for better diagnostic tools and more effective treatments.
Interestingly, within the broader asthma diagnosis, there are two primary subgroups: Intermittent and Persistent asthma. The latter, which includes mild, moderate, and severe cases, accounts for the majority of asthma cases. This growing number of severe asthma diagnoses is prompting an increased focus on tailored therapies and more personalized approaches to care.
One of the most exciting developments in the severe asthma market is the improvement in diagnostic approaches. A better understanding of asthma’s underlying mechanisms—particularly the differences between Type-2 and non-Type-2 inflammation—has allowed for more precise diagnosis and treatment strategies. These advancements in diagnostics are helping healthcare professionals identify severe asthma more accurately, enabling earlier intervention and more effective treatment.
Additionally, the introduction of biologic therapies has revolutionized the treatment of severe asthma. These targeted therapies, such as Dupixent (dupilumab), are expected to dominate the market in the coming years, with Dupixent projected to hold the largest market share by 2034. Biologics, designed to modulate the immune system’s response to inflammation, offer significant advantages over traditional treatments, providing relief to patients who do not respond to conventional asthma medications.
Currently, six monoclonal antibodies are approved for the treatment of severe asthma, and more are in the pipeline. The increasing availability of these biologic treatments is expected to contribute significantly to the market’s growth, offering new hope for patients who have long struggled with poorly controlled asthma.
Despite the promising developments in asthma care, there remain several barriers that hinder the market’s full potential. One of the most significant challenges is the high cost of treatment. The price of biologic therapies, in particular, can be prohibitive, creating access issues for patients, especially in low- and middle-income countries.
In this regard, the market is facing an urgent need for solutions that address these unmet medical needs. The launch of more affordable therapies, improved patient education, and streamlined diagnostic processes are all key factors that will drive the next phase of growth in the severe asthma market.
Looking ahead, the severe asthma market is poised for significant expansion. Projections suggest that the therapeutic market will experience a substantial compound annual growth rate (CAGR) from 2024 to 2034, fueled by the expected approval of new treatments and the ongoing improvement of existing therapies. As pharmaceutical companies continue to innovate and bring new biologic treatments to market, patients with severe asthma will have access to increasingly effective options.
Furthermore, ongoing research in asthma pathophysiology, such as the exploration of non-eosinophilic asthma and other less understood forms of the disease, holds the potential for breakthroughs in treatment. These advancements could help address the large patient population that remains underserved by current therapies.
The severe asthma market is highly competitive, with several major pharmaceutical companies leading the charge in developing new treatments. Some of the key players in the space include AstraZeneca, GlaxoSmithKline, Amgen, Teva Pharmaceutical Industries, Novartis, and Regeneron Pharmaceutical, among others. These companies are investing heavily in research and development to bring new solutions to the market, particularly biologics that target specific aspects of asthma pathology.
The severe asthma market is at a turning point, driven by advances in diagnostics, the launch of groundbreaking therapies, and the growing recognition of the disease’s complexity. While challenges remain—particularly regarding treatment costs and access—there is significant optimism about the future. The ongoing investment in research and the development of more personalized treatment options promise a brighter future for patients, offering hope for better control over this challenging condition.
As we look ahead to 2034, the severe asthma market will likely continue to expand, driven by innovations in care, improving patient outcomes, and the growing understanding of asthma’s underlying mechanisms. With these advancements, the outlook for both patients and the healthcare industry is one of increased hope and opportunity.
G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.
Contact us today to learn more: Contact@g-med.com